vs
Esperion Therapeutics, Inc.（ESPR）与GCM Grosvenor Inc.（GCMG）财务数据对比。点击上方公司名可切换其他公司
GCM Grosvenor Inc.的季度营收约是Esperion Therapeutics, Inc.的1.1倍（$177.1M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 7.2%），过去两年GCM Grosvenor Inc.的营收复合增速更高（27.5% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
GCM Grosvenor是美国头部另类资产管理机构，截至2023年资产管理规模约760亿美元，拥有约530名专业人士，为全球机构及个人投资者提供定制化另类投资解决方案，覆盖私募股权、对冲基金、房地产、基础设施等多元资产类别。
ESPR vs GCMG — 直观对比
营收规模更大
GCMG
是对方的1.1倍
$168.4M
营收增速更快
ESPR
高出136.6%
7.2%
两年增速更快
GCMG
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $177.1M |
| 净利润 | — | $58.2M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 30.9% |
| 净利率 | — | 32.8% |
| 营收同比 | 143.7% | 7.2% |
| 净利润同比 | — | 149.2% |
| 每股收益（稀释后） | $0.32 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRGCMG
| Q4 25 | $168.4M | $177.1M | ||
| Q3 25 | $87.3M | $135.0M | ||
| Q2 25 | $82.4M | $119.7M | ||
| Q1 25 | $65.0M | $125.8M | ||
| Q4 24 | $69.1M | $165.3M | ||
| Q3 24 | $51.6M | $122.9M | ||
| Q2 24 | $73.8M | $117.0M | ||
| Q1 24 | $137.7M | $108.9M |
净利润ESPRGCMG
| Q4 25 | — | $58.2M | ||
| Q3 25 | $-31.3M | $10.5M | ||
| Q2 25 | $-12.7M | $15.4M | ||
| Q1 25 | $-40.5M | $463.0K | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $-29.5M | $4.2M | ||
| Q2 24 | $-61.9M | $4.8M | ||
| Q1 24 | $61.0M | $2.1M |
营业利润率ESPRGCMG
| Q4 25 | 50.6% | 30.9% | ||
| Q3 25 | -11.4% | 32.7% | ||
| Q2 25 | 8.6% | 16.1% | ||
| Q1 25 | -34.0% | 12.2% | ||
| Q4 24 | -6.4% | 26.4% | ||
| Q3 24 | -31.0% | 20.3% | ||
| Q2 24 | 3.5% | 17.8% | ||
| Q1 24 | 52.5% | -14.7% |
净利率ESPRGCMG
| Q4 25 | — | 32.8% | ||
| Q3 25 | -35.9% | 7.8% | ||
| Q2 25 | -15.4% | 12.9% | ||
| Q1 25 | -62.2% | 0.4% | ||
| Q4 24 | — | 4.6% | ||
| Q3 24 | -57.2% | 3.4% | ||
| Q2 24 | -83.9% | 4.1% | ||
| Q1 24 | 44.3% | 2.0% |
每股收益（稀释后）ESPRGCMG
| Q4 25 | $0.32 | $0.23 | ||
| Q3 25 | $-0.16 | $0.16 | ||
| Q2 25 | $-0.06 | $0.05 | ||
| Q1 25 | $-0.21 | $-0.02 | ||
| Q4 24 | $-0.14 | $0.09 | ||
| Q3 24 | $-0.15 | $0.03 | ||
| Q2 24 | $-0.33 | $0.04 | ||
| Q1 24 | $0.34 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $242.1M |
| 总债务越低越好 | — | $428.4M |
| 股东权益账面价值 | $-302.0M | $27.0M |
| 总资产 | $465.9M | $813.8M |
| 负债/权益比越低杠杆越低 | — | 15.87× |
8季度趋势，按日历期对齐
现金及短期投资ESPRGCMG
| Q4 25 | $167.9M | $242.1M | ||
| Q3 25 | $92.4M | $182.7M | ||
| Q2 25 | $86.1M | $136.3M | ||
| Q1 25 | $114.6M | $94.5M | ||
| Q4 24 | $144.8M | $89.5M | ||
| Q3 24 | $144.7M | $98.4M | ||
| Q2 24 | $189.3M | $73.9M | ||
| Q1 24 | $226.6M | $41.9M |
总债务ESPRGCMG
| Q4 25 | — | $428.4M | ||
| Q3 25 | — | $429.3M | ||
| Q2 25 | — | $430.2M | ||
| Q1 25 | — | $431.1M | ||
| Q4 24 | — | $432.0M | ||
| Q3 24 | — | $432.9M | ||
| Q2 24 | — | $433.8M | ||
| Q1 24 | — | $384.0M |
股东权益ESPRGCMG
| Q4 25 | $-302.0M | $27.0M | ||
| Q3 25 | $-451.4M | $-7.4M | ||
| Q2 25 | $-433.5M | $-12.3M | ||
| Q1 25 | $-426.2M | $-28.3M | ||
| Q4 24 | $-388.7M | $-27.6M | ||
| Q3 24 | $-370.2M | $-31.9M | ||
| Q2 24 | $-344.2M | $-28.5M | ||
| Q1 24 | $-294.3M | $-26.4M |
总资产ESPRGCMG
| Q4 25 | $465.9M | $813.8M | ||
| Q3 25 | $364.0M | $685.9M | ||
| Q2 25 | $347.1M | $636.9M | ||
| Q1 25 | $324.0M | $579.8M | ||
| Q4 24 | $343.8M | $612.7M | ||
| Q3 24 | $314.1M | $575.0M | ||
| Q2 24 | $352.3M | $543.9M | ||
| Q1 24 | $373.1M | $497.3M |
负债/权益比ESPRGCMG
| Q4 25 | — | 15.87× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $183.5M |
| 自由现金流经营现金流 - 资本支出 | — | $175.0M |
| 自由现金流率自由现金流/营收 | — | 98.8% |
| 资本支出强度资本支出/营收 | 0.0% | 4.8% |
| 现金转化率经营现金流/净利润 | — | 3.16× |
| 过去12个月自由现金流最近4个季度 | — | $326.2M |
8季度趋势，按日历期对齐
经营现金流ESPRGCMG
| Q4 25 | $45.2M | $183.5M | ||
| Q3 25 | $-4.3M | $79.8M | ||
| Q2 25 | $-31.4M | $42.0M | ||
| Q1 25 | $-22.6M | $33.3M | ||
| Q4 24 | $-35.0M | $148.8M | ||
| Q3 24 | $-35.3M | $69.0M | ||
| Q2 24 | $-7.2M | $17.5M | ||
| Q1 24 | $53.8M | $24.2M |
自由现金流ESPRGCMG
| Q4 25 | — | $175.0M | ||
| Q3 25 | — | $78.3M | ||
| Q2 25 | — | $40.8M | ||
| Q1 25 | — | $32.1M | ||
| Q4 24 | — | $132.0M | ||
| Q3 24 | $-35.5M | $62.2M | ||
| Q2 24 | $-7.3M | $12.8M | ||
| Q1 24 | $53.8M | $20.0M |
自由现金流率ESPRGCMG
| Q4 25 | — | 98.8% | ||
| Q3 25 | — | 58.0% | ||
| Q2 25 | — | 34.1% | ||
| Q1 25 | — | 25.5% | ||
| Q4 24 | — | 79.9% | ||
| Q3 24 | -68.7% | 50.6% | ||
| Q2 24 | -9.9% | 10.9% | ||
| Q1 24 | 39.0% | 18.4% |
资本支出强度ESPRGCMG
| Q4 25 | 0.0% | 4.8% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 10.1% | ||
| Q3 24 | 0.3% | 5.5% | ||
| Q2 24 | 0.1% | 4.0% | ||
| Q1 24 | 0.1% | 3.9% |
现金转化率ESPRGCMG
| Q4 25 | — | 3.16× | ||
| Q3 25 | — | 7.61× | ||
| Q2 25 | — | 2.72× | ||
| Q1 25 | — | 71.84× | ||
| Q4 24 | — | 19.54× | ||
| Q3 24 | — | 16.60× | ||
| Q2 24 | — | 3.64× | ||
| Q1 24 | 0.88× | 11.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
GCMG
| Asset Management1 | $108.6M | 61% |
| Management Service Incentive Performance Fees | $61.7M | 35% |
| Management Service Incentive Carried Interest | $5.1M | 3% |
| Service Other | $1.8M | 1% |
